中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

协同创新理念下区域性肝脏病理中心科研体系建设的实践与思考

汤鸿 朱颖炜 陆忠华

汤鸿,朱颖炜,陆忠华. 协同创新理念下区域性肝脏病理中心科研体系建设的实践与思考[J]. 临床肝胆病杂志, 2021, 37(9): 2167-2170. DOI: 10.3969/j.issn.1001-5256.2021.09.031
引用本文: 汤鸿,朱颖炜,陆忠华. 协同创新理念下区域性肝脏病理中心科研体系建设的实践与思考[J]. 临床肝胆病杂志, 2021, 37(9): 2167-2170. DOI: 10.3969/j.issn.1001-5256.2021.09.031
TANG H, ZHU YW, LU ZH. Practice and thinking on constructing a scientific research system for regional liver pathology center under the concept of collaborative innovation[J]. J Clin Hepatol, 2021, 37(9): 2167-2170. DOI: 10.3969/j.issn.1001-5256.2021.09.031
Citation: TANG H, ZHU YW, LU ZH. Practice and thinking on constructing a scientific research system for regional liver pathology center under the concept of collaborative innovation[J]. J Clin Hepatol, 2021, 37(9): 2167-2170. DOI: 10.3969/j.issn.1001-5256.2021.09.031

协同创新理念下区域性肝脏病理中心科研体系建设的实践与思考

DOI: 10.3969/j.issn.1001-5256.2021.09.031
基金项目: 

无锡市科学技术协会重点软课题项目 KX-20-B64

详细信息
    通讯作者:

    陆忠华,Lu_z_h@126.com

  • 中图分类号: R575

Practice and thinking on constructing a scientific research system for regional liver pathology center under the concept of collaborative innovation

Funds: 

Key Soft Project of Wuxi Science and Technology Association KX-20-B64

  • 摘要:   目的  多角度分析协同创新理念实践对区域性肝脏病理中心科研体系建设的影响,初步探讨其应用意义。  方法  收集2014年1月—2020年9月于无锡市第二人民医院、无锡市第五人民医院病理科检测的1246例肝活检标本,其中区域性肝脏病理中心成立前的为nⅠ组,成立后的为nⅡ组,并将nⅡ组按照成立后第1、2、3年分为nⅡa组、n Ⅱ b组、n Ⅱ c组,以肝活检标本数量、肝活检标本增长率、内部协同科室数量增长率、外部协同单位增长率、协同创新科研体系评价共5项指标进行多角度分析。  结果  n Ⅰ组的肝活检标本增长率为15.51%,组建区域性肝脏病理中心后nⅡa组增长率最高,为187.76%,nⅡb组增长率较稳定,为76.35%;内部协同科室标本量呈现持续性增长,nⅡa组为50%,nⅡb组升高至83.33%,而外部协作单位表现为稳定性增长,nⅡa组为100%,nⅡb组为50%;在科研体系评价指标中nⅡ组呈现多样化增长趋势。  结论  协同创新理念下把握政策支持性发展的机遇,创新内部科室和外部单位的有效协作方式是区域性学科科研体系建设参考的新视角。

     

  • 图  1  3组肝活检标本量的比较

    图  2  不同协同方式在nⅡ两组标本量变化中的比较

    图  3  不同协同方式在nⅡ两组科研体系评价变化中的比较

    注:数字代表各不同颜色区域内的数量。

  • [1] GAO HJ. Practice and thinking on the construction of new clinical medicine discipline of "patient-centered"[J]. Natl Med J China, 2020, 11(40): 3126-3129. DOI: 10.3760/cma.j.cn112137-20200324-00911.

    郜恒骏. "以患者为中心"新型临床医学学科建设的实践与思考[J]. 中华医学杂志, 2020, 11(40): 3126-3129. DOI: 10.3760/cma.j.cn112137-20200324-00911.
    [2] VERONICA S, THOMAS F. Collaborative innovation in ubiquitous systems[J]. J Intell Manuf, 2007, 18(5): 599-615. DOI: 10.1007/s10845-007-0064-2.
    [3] HINRICHS MM, SEAGER TP, TRACY SJ, et al. Innovation in the knowledge age: Implications for collaborative science[J]. Environ Syst Decis, 2017, 37(2): 144-155. DOI: 10.1007/s10669-016-9610-9.
    [4] van WEEL C, TURNBULL D, WHITEHEAD E, et al. International collaboration in innovating health systems[J]. Ann Fam Med, 2015, 13(1): 86-87. DOI: 10.1370/afm.1751.
    [5] GOUGET B, TOUIMI B, JELLOUN M. The fifbcml: A mediterranean-leading platform for collaboration and innovation in lab medical[J]. Clin Chem Lab Med, 2017, 55: s131. DOI: 10.1515/cclm-2017-5001.
    [6] RUAN B, YU Z, YANG S, et al. Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China[J]. BMC Infect Dis, 2019, 19(1): 617. DOI: 10.1186/s12879-019-4150-9.
    [7] POYAN MEHR A, SADEGHI-NAJAFABADI M, CHAU K, et al. The glomerular disease study and trial consortium: A grassroots initiative to foster collaboration and innovation[J]. Kidney Int Rep, 2019, 4(1): 20-29. DOI: 10.1016/j.ekir.2018.09.012.
    [8] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [9] XIAO J, WANG F, WONG NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019, 71(1): 212-221. DOI: 10.1016/j.jhep.2019.03.004.
    [10] TAPPER EB, LOK AS. Use of liver imaging and biopsy in clinical practice[J]. N Eng J Med, 2017, 377(8): 756-768. DOI: 10.1056/NEJMra1610570.
    [11] TORBENSON M, WASHINGTON K. Pathology of liver disease: Advances in the last 50 years[J]. Hum Pathol, 2020, 95: 78-98. DOI: 10.1016/j.humpath.2019.08.023.
    [12] TANG H, XU RR, JIANG LL, et al. A study of construction strategy for regional clinical pathology center of liver disease based on SWOT analysis[J]. J Clin Hepatol, 2019, 35(7): 1582-1584. DOI: 10.3969/j.issn.1001-5256.2019.07.031.

    汤鸿, 徐蓉蓉, 蒋丽琳, 等. 基于SWOT分析法的区域性肝病临床病理研究中心建设策略[J]. 临床肝胆病杂志, 2019, 35(7): 1582-1584. DOI: 10.3969/j.issn.1001-5256.2019.07.031.
    [13] FU L, YIN L, ZHU ML, et al. Innovation system construction for China's basic and clinical medcine[J]. Eng Sci, 2017, 19(2): 72-78. DOI: 10.15302/J-SSCAE-2017.02.012.

    付磊, 尹岭, 朱曼璐, 等. 我国基础与临床医学创新体系建设研究[J]. 中国工程科学, 2017, 19(2): 72-78. DOI: 10.15302/J-SSCAE-2017.02.012.
    [14] ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. DOI: 10.1053/j.gastro.2019.11.312.
    [15] TANAKA N, KIMURA T, FUJIMORI N, et al. Current status, problems, and perspectives of non-alcoholic fatty liver disease research[J]. World J Gastroenterol, 2019, 25(2): 163-177. DOI: 10.3748/wjg.v25.i2.163.
    [16] LI LJ, ZHENG SS, CHEN Z, et al. Theoretical innovation and technical breakthrough in the diagnosis and treatment of severe liver disease[J]. China Sci Technol Achievements, 2014, 15(1): 64-66. DOI: 10.3772/j.issn.1009-5659.2014.01.025.

    李兰娟, 郑树森, 陈智, 等. 重症肝病诊治的理论创新与技术突破[J]. 中国科技成果, 2014, 15(1): 64-66. DOI: 10.3772/j.issn.1009-5659.2014.01.025.
    [17] CHESBROUGH H. Open innovation: Where we've been and where we're going: The father of open innovation offers his assessment of the history and future of the model[J]. Res Technol Manage, 2012, 55(4): 20-27. DOI: 10.5437/08956308X5504085.
  • 加载中
图(3)
计量
  • 文章访问数:  30
  • HTML全文浏览量:  9
  • PDF下载量:  7
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-01-10
  • 修回日期:  2021-04-12
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回